Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haraldur Þorsteinsson

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Frontiers in Behavioral Neuroscience|January 4, 2021
Multi-parameter Behavioral Phenotyping of the MPP+ Model of Parkinson's Disease in ZebrafishChristian Christensen, Haraldur Þorsteinsson, Valerie Helene Maier, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 15, 2026
Reinventing amlodipineBartosz Grzymala, Dagmar Þöll Halldórsdóttir, Haraldur Þorsteinsson, et al.
Plos One|January 5, 2022
Motility phenotype in a zebrafish vmat2 mutantHildur Sóley Sveinsdóttir, Amanda Decker, Christian Christensen, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 13, 2025
Metabolomic and lipidomic profiling reveals convergent pathways in attention deficit hyperactivity disorder therapeutics: Insights from established and emerging treatmentsBartosz Grzymala, Haraldur Þorsteinsson, Dagmar Þöll Halldórsdóttir, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 18, 2022
Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHDHildur Sóley Sveinsdóttir, Christian Christensen, Haraldur Þorsteinsson, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 14, 2025
Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical recordsHaraldur Þorsteinsson, Hannes A Baukmann, Hildur S Sveinsdóttir, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Frontiers in Behavioral Neuroscience|January 4, 2021
Multi-parameter Behavioral Phenotyping of the MPP+ Model of Parkinson's Disease in ZebrafishChristian Christensen, Haraldur Þorsteinsson, Valerie Helene Maier, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 15, 2026
Reinventing amlodipineBartosz Grzymala, Dagmar Þöll Halldórsdóttir, Haraldur Þorsteinsson, et al.
Plos One|January 5, 2022
Motility phenotype in a zebrafish vmat2 mutantHildur Sóley Sveinsdóttir, Amanda Decker, Christian Christensen, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 13, 2025
Metabolomic and lipidomic profiling reveals convergent pathways in attention deficit hyperactivity disorder therapeutics: Insights from established and emerging treatmentsBartosz Grzymala, Haraldur Þorsteinsson, Dagmar Þöll Halldórsdóttir, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 18, 2022
Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHDHildur Sóley Sveinsdóttir, Christian Christensen, Haraldur Þorsteinsson, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 14, 2025
Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical recordsHaraldur Þorsteinsson, Hannes A Baukmann, Hildur S Sveinsdóttir, et al.
Pageof 1